罗格列酮对癌性条件下肝星状细胞表达PDGF-B、α-SMA的影响  

Effect of Rosiglitazone on Expression of PDGF-B,α-SMA in HSC Cultured under Carcinous Condition

作　　者：罗波[1] 官阳[2] 袁静萍[1] 杨木兰[2] 徐惠[2] 石玉香[1] 

机构地区：[1]武汉市中心医院病理科,武汉430014 [2]华中科技大学同济医学院超微病理室

出　　处：《肿瘤防治研究》2011年第2期141-143,共3页Cancer Research on Prevention and Treatment

摘　　要：目的观察罗格列酮对癌性条件下生长的肝星状细胞表达PDGF-B和α-SMA的影响。方法肝星状细胞(HSC)经肝癌细胞(HCC)条件培养液(按1∶1、1∶2的比例稀释)处理24h后,再用15μmol/L罗格列酮处理HSC24h(另设空白对照组、单纯罗格列酮组和单纯24h肝癌细胞条件培养液组)。观察肝星状细胞表达PDGF-B、α-SMA表达变化。结果罗格列酮作用于经肝癌细胞条件培养液处理后的HSC,α-SMA和PDGF-B的表达,均有显著下降(P<0.05)。结论罗格列酮可以抑制癌性条件下生长的HSC的活化和PDGF-B的表达。Objective To observe the effect of Rosiglitazone on the expression of PDGF-B,α-SMA in HSC cultured under carcinous condition.Methods HSC were at first exposed to 24h conditioned medium from HepG2（1 ∶ 1 and 1 ∶ 2 dilution） and then treated with Rosiglitazone（15μmol/L）,expression levels of PDGF-B,α-SMA in HSC was checked by IHC.Control group,only Rosiglitazone treatment group and only conditioned medium treatment group were also arranged.Results HSC were at first exposed to 24h conditioned medium from HepG2 and then treated with Rosiglitazone（15μmol/L）,expression of α-SMA（0.2767±0.03692,0.2736±0.0418）,PDGF-B（0.2542±0.03917,0.2401±0.01941） in HSC was decreased significantly（P0.05） compared with that in the control group（0.2863±0.03507,0.3150±0.03435） and only conditioned medium treatment group（0.3753±0.07636,0.3512±0.0345）.Conclusion Rosiglitazone could inhibit the activation and expression of PDGF and α-SMA in HSC cultured under carcinous condition.

关 键 词：罗格列酮 肝星状细胞 血小板衍生因子 Α-平滑肌肌动蛋白 

分 类 号：R735.7[医药卫生—肿瘤] R975.5[医药卫生—临床医学]